Published:
•ID: 4433514
•Pages: 109
Interleukin Inhibitors
for Psoriasis
Asia-Pacific Interleukin Inhibitors for Psoriasis Market Size, Growth & Revenue 2024-2034
Asia-Pacific Interleukin Inhibitors for Psoriasis Market is segmented by Application (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis), Type (IL-17 Inhibitors, IL-23 Inhibitors, IL-12/23 Inhibitors, IL-36 Inhibitors, Others), and Geography (Japan, China, Southeast Asia, India, Australia, South Korea, Others)
Report ID:
HTF4433514
Published:
CAGR:
14.8%
Market Size (2025):
$1.45 Billion
Forecast (2034):
$5.85 Billion
Pricing
Report Overview
Executive Summary
- •The Asia-Pacific Interleukin Inhibitors for Psoriasis market consists of biologic drugs targeting interleukin pathways such as IL-17, IL-23, and IL-12/23 to treat various psoriasis types. It addresses immune-mediated skin inflammation with high efficacy and fewer side effects compared to traditional treatments.
- •Key market highlights include robust CAGR of 14.8% from 2024 to 2034, driven by rising psoriasis prevalence, increasing healthcare expenditure, and expanding biologic therapy adoption across major Asia-Pacific countries.
- •The market holds significant value for pharmaceutical companies, healthcare providers, and patients by offering targeted, innovative therapies that improve quality of life and reduce disease burden in the region’s diverse populations.
Competitive Landscape
The Asia-Pacific Interleukin Inhibitors for Psoriasis market features intense competition among global pharmaceutical giants and emerging regional players. Companies emphasize innovation through R&D in biologics and biosimilars, strategic partnerships, and product pipeline expansion. Market positioning relies on efficacy, safety profiles, regulatory approvals, and pricing strategies. Competitive dynamics include rapid adoption of novel IL inhibitors, differentiation via targeted therapies, regional manufacturing capabilities, and expanding access via healthcare infrastructure development. Mergers and acquisitions complement organic growth to consolidate market share. Rivalry is also shaped by reimbursement policies and patient awareness campaigns, with digital engagement increasingly influencing market reach and adoption.
Leading Companies in Asia-Pacific Interleukin Inhibitors for Psoriasis Market
- •AbbVie Inc. (United States)
- •Novartis AG (Switzerland)
- •Eli Lilly and Company (United States)
- •Johnson & Johnson (United States)
- •Bristol-Myers Squibb Company (United States)
- •Samsung Bioepis Co., Ltd. (South Korea)
- •Biocon Limited (India)
- •Shanghai Henlius Biotech, Inc. (China)
- •Fujifilm Pharma Co., Ltd. (Japan)
- •Celltrion Healthcare Co., Ltd. (South Korea)
- •Mylan N.V. (United States)
- •Pfizer Inc. (United States)
- •Takeda Pharmaceutical Company Limited (Japan)
- •Amgen Inc. (United States)
- •Sun Pharmaceutical Industries Ltd. (India)
- •Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
- •AstraZeneca PLC (United Kingdom)
- •GlaxoSmithKline plc (United Kingdom)
- •UCB S.A. (Belgium)
- •Lupin Limited (India)
- •Bio-Thera Solutions, Ltd. (China)
- •Mitsubishi Tanabe Pharma Corporation (Japan)
- •Cipla Limited (India)
- •Hikma Pharmaceuticals PLC (United Kingdom)
- •Innovent Biologics, Inc. (China)
Asia-Pacific Interleukin Inhibitors for Psoriasis Market Segmentation
- •By Type
- ◦IL-17 Inhibitors (e.g., Secukinumab, Ixekizumab)
- ◦IL-23 Inhibitors (e.g., Guselkumab, Risankizumab)
- ◦IL-12/23 Inhibitors (e.g., Ustekinumab)
- ◦IL-36 Inhibitors
- ◦Others (Emerging biologics)
- •By Application
- ◦Plaque Psoriasis
- ◦Guttate Psoriasis
- ◦Inverse Psoriasis
- ◦Pustular Psoriasis
- ◦Erythrodermic Psoriasis
- •By End User
- ◦Hospitals and Clinics
- ◦Specialty Dermatology Centers
- ◦Outpatient Care Facilities
- ◦Home Healthcare Services
- •By Distribution Channel
- ◦Hospital Pharmacies
- ◦Retail Pharmacies
- ◦Online Pharmacies
- ◦Direct Sales
Growth Drivers
- •Rising prevalence of psoriasis in Asia-Pacific, particularly in urban centers, fuels demand for targeted interleukin inhibitors offering improved treatment outcomes and quality of life.
- •Advancements in biologic therapies with higher efficacy and safety profiles compared to traditional systemic treatments encourage wider adoption among healthcare providers and patients.
- •Expanding healthcare infrastructure and increasing government initiatives to improve access to innovative therapies drive market penetration across emerging Asia-Pacific economies.
- •Growing awareness and diagnosis rates due to improved dermatological screening and patient education enhance market growth opportunities.
- •Strategic partnerships and collaborations among pharmaceutical companies accelerate product launches and distribution networks across the region.
Market Trends
- •Rising adoption of personalized medicine approaches targeting specific interleukin pathways optimizes treatment efficacy and minimizes adverse effects.
- •Increased development and approval of biosimilars reduce treatment costs and improve accessibility in price-sensitive Asia-Pacific markets.
- •Integration of digital health platforms facilitates remote patient monitoring and treatment adherence, enhancing therapeutic outcomes.
- •Expansion of clinical trials focusing on diverse Asia-Pacific populations supports tailored drug development and regulatory approvals.
- •Sustainability initiatives in manufacturing and packaging align with regional regulations and consumer preferences for eco-friendly products.
Market Restraints
- •High cost of biologic interleukin inhibitors limits patient access in lower-income Asia-Pacific countries despite growing demand.
- •Stringent regulatory approval processes and varying country-specific requirements delay product launches and market entry.
- •Limited awareness and diagnosis in rural areas restrict market penetration and timely treatment initiation.
- •Potential side effects and long-term safety concerns reduce physician and patient willingness to adopt newer therapies.
- •Supply chain complexities and pricing pressures from biosimilar entrants challenge market profitability.
Market Opportunities
- •Emerging markets like India and Southeast Asia present high growth potential due to increasing healthcare expenditure and expanding patient base.
- •Development of next-generation interleukin inhibitors with enhanced specificity and reduced immunogenicity can capture unmet clinical needs.
- •Collaborations with local firms enable cost-effective production and faster regulatory approvals across Asia-Pacific countries.
- •Integration of artificial intelligence in drug discovery and patient management optimizes treatment personalization and market responsiveness.
- •Increasing government reimbursement schemes improve affordability and patient access to advanced biologic treatments.
Market Challenges
- •Managing heterogeneous regulatory frameworks across Asia-Pacific countries complicates market entry and compliance strategies for pharmaceutical companies.
- •Ensuring consistent drug supply and cold chain logistics in remote and underdeveloped areas remains a significant operational hurdle.
- •Competition from conventional therapies and emerging small-molecule drugs limits biologic market share expansion.
- •Pricing pressures from biosimilars and generic manufacturers challenge profitability and investment in R&D.
- •Educating healthcare professionals and patients about the benefits and risks of interleukin inhibitors requires sustained efforts and resources.
Regulatory Framework
- •Between 2022 and 2024, Asia-Pacific regulatory authorities including China’s NMPA and India’s CDSCO have streamlined approval pathways for biologics, incorporating expedited review processes for breakthrough therapies.
- •Harmonization initiatives by ASEAN and regional regulatory forums aim to standardize clinical trial requirements and pharmacovigilance standards across member countries.
- •Regulations emphasize stringent quality control, biosimilar comparability, and post-marketing surveillance to ensure patient safety and product efficacy.
- •Government incentives and reimbursement policies in Japan, South Korea, and Australia promote access to innovative interleukin inhibitors for psoriasis treatment.
- •Compliance with environmental and manufacturing guidelines aligned with WHO standards is mandatory for market authorization and sustained supply.
Industry Insights
- •In March 2024, a leading pharmaceutical company launched a novel IL-23 inhibitor tailored for the Asia-Pacific market, demonstrating superior efficacy in plaque psoriasis patients during regional clinical trials. This launch is expected to enhance treatment options and expand patient access significantly.
- •By November 2023, strategic collaborations between South Korean biotech firms and global pharma leaders accelerated biosimilar development, aiming to reduce costs and increase biological therapy penetration in underserved markets across Southeast Asia.
Mergers & Acquisitions
- •In July 2024, a major global biopharmaceutical company acquired a prominent Asia-Pacific biosimilars manufacturer to strengthen its biologics portfolio, particularly interleukin inhibitors. This acquisition enables expanded regional manufacturing capabilities and accelerates local market entry for novel therapies.
- •In January 2023, a leading Japanese pharmaceutical firm merged with an Indian biotech specialist to jointly develop and commercialize next-generation interleukin inhibitors. The partnership enhances R&D synergies and broadens access to emerging Asia-Pacific markets.
Recent Industry News
- •15th January 2025, Biocon Limited announced the launch of its biosimilar IL-17 inhibitor in India and Southeast Asia, aiming to provide affordable treatment options. The product demonstrated promising clinical trial results and received regulatory approvals across multiple countries. This launch is expected to disrupt pricing dynamics in the region. Source: Official Biocon press release
- •10th March 2025, Novartis AG entered a strategic partnership with a South Korean biotech company to co-develop IL-23 biologics for psoriasis, leveraging local expertise and manufacturing facilities. The collaboration focuses on accelerating clinical development and market penetration in Asia-Pacific. Source: Novartis corporate announcement
- •22nd May 2025, Eli Lilly and Company expanded its distribution network in Australia and New Zealand for its recently approved IL-12/23 inhibitor, enhancing access for patients with moderate to severe psoriasis. The expansion includes digital patient support programs to improve treatment adherence. Source: Eli Lilly official news
- •8th July 2025, Samsung Bioepis Co., Ltd. announced the initiation of a large-scale clinical trial for its novel IL-36 inhibitor across multiple Asia-Pacific countries, aiming to address rare psoriasis subtypes. This trial marks a significant step in diversifying therapeutic options in the region. Source: Samsung Bioepis press statement
Market Statistics
- •CAGR by 2034: 14.8%
- •Market Size by 2034: USD 5.85 Billion
- •Market Size in 2025: USD 1.67 Billion
- •Dominating Type: IL-17 Inhibitors; Next-Following Type: IL-23 Inhibitors
- •Dominating Application: Plaque Psoriasis; Next-Following Application: Guttate Psoriasis
- •Dominating Region: China; Second-Leading Region: Japan
- •Region with Highest Growth Rate: India
- •Dominating Country: China
Market Share Table
- •Market Share of Dominating Type (IL-17 Inhibitors): 45% vs Followed Type (IL-23 Inhibitors): 28%
- •Market Share of Dominating Application (Plaque Psoriasis): 50% vs Followed Application (Guttate Psoriasis): 20%
- •Growth Rate of Dominating Type (IL-17 Inhibitors): 13.5% vs Followed Type (IL-23 Inhibitors): 18.2%
- •Growth Rate of Dominating Application (Plaque Psoriasis): 14.0% vs Followed Application (Guttate Psoriasis): 16.5%
Top 5 Global Players
- •AbbVie Inc. (United States)
- •Novartis AG (Switzerland)
- •Eli Lilly and Company (United States)
- •Johnson & Johnson (United States)
- •Bristol-Myers Squibb Company (United States)
Regional Outlook
The China currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, India is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth.
In our report, we cover a comprehensive analysis of the following regions and countries:
- Japan
- China
- Southeast Asia
- India
- Australia
- South Korea
- Others
Loading map...
| Feature | Details |
|---|---|
| Base Year Market Size | USD 1.45 Billion |
| Forecast Year Market Size | USD 5.85 Billion |
| CAGR | 14.8% |
| Forecast Period | 2026 to 2033 |
| YoY Growth | 14% |
| Regions Covered | Japan, China, Southeast Asia, India, Australia, South Korea, Others |
| Key Companies | AbbVie Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), Bristol-Myers Squibb Company (United States), Samsung Bioepis Co., Ltd. (South Korea), Biocon Limited (India), Shanghai Henlius Biotech, Inc. (China), Fujifilm Pharma Co., Ltd. (Japan), Celltrion Healthcare Co., Ltd. (South Korea), Mylan N.V. (United States), Pfizer Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), AstraZeneca PLC (United Kingdom), GlaxoSmithKline plc (United Kingdom), UCB S.A. (Belgium), Lupin Limited (India), Bio-Thera Solutions, Ltd. (China), Mitsubishi Tanabe Pharma Corporation (Japan), Cipla Limited (India), Hikma Pharmaceuticals PLC (United Kingdom), Innovent Biologics, Inc. (China) |
Asia-Pacific Interleukin Inhibitors for Psoriasis Market Size, Growth & Revenue 2024-2034 - Table of Contents
Frequently Asked Questions (FAQ):
The Compact Track Loaders market is projected to grow at a CAGR of 6.8% from 2025 to 2030, driven by increasing demand in construction and agricultural sectors.
North America currently leads the market with approximately 45% market share, followed by Europe at 28% and Asia-Pacific at 22%. The remaining regions account for 5% of the global market.
Key growth drivers include increasing construction activities, rising demand for versatile equipment in agriculture, technological advancements in track loader design, and growing preference for compact equipment in urban construction projects.